DD221917A5 - Verfahren zur herstellung von krebszellen-cytotoxischen lymphocyten - Google Patents
Verfahren zur herstellung von krebszellen-cytotoxischen lymphocyten Download PDFInfo
- Publication number
- DD221917A5 DD221917A5 DD82261475A DD26147582A DD221917A5 DD 221917 A5 DD221917 A5 DD 221917A5 DD 82261475 A DD82261475 A DD 82261475A DD 26147582 A DD26147582 A DD 26147582A DD 221917 A5 DD221917 A5 DD 221917A5
- Authority
- DD
- German Democratic Republic
- Prior art keywords
- lectin
- gra
- cancer
- cells
- lymphocytes
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 88
- 201000011510 cancer Diseases 0.000 title claims abstract description 79
- 238000000034 method Methods 0.000 title claims abstract description 57
- 210000004698 lymphocyte Anatomy 0.000 title claims abstract description 40
- 238000004519 manufacturing process Methods 0.000 title claims description 7
- 230000001472 cytotoxic effect Effects 0.000 title claims description 6
- 231100000433 cytotoxic Toxicity 0.000 title claims description 5
- 210000004027 cell Anatomy 0.000 claims abstract description 153
- 108090001090 Lectins Proteins 0.000 claims abstract description 51
- 102000004856 Lectins Human genes 0.000 claims abstract description 51
- 239000002523 lectin Substances 0.000 claims abstract description 51
- 210000000170 cell membrane Anatomy 0.000 claims abstract description 13
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 claims abstract description 11
- 239000000427 antigen Substances 0.000 claims abstract description 11
- 102000036639 antigens Human genes 0.000 claims abstract description 11
- 108091007433 antigens Proteins 0.000 claims abstract description 11
- 229930182830 galactose Natural products 0.000 claims abstract description 11
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000002609 medium Substances 0.000 claims description 30
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 17
- 239000012894 fetal calf serum Substances 0.000 claims description 17
- 108010046016 Peanut Agglutinin Proteins 0.000 claims description 15
- 210000002966 serum Anatomy 0.000 claims description 11
- 206010070834 Sensitisation Diseases 0.000 claims description 4
- 230000008313 sensitization Effects 0.000 claims description 4
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 claims description 3
- 238000000265 homogenisation Methods 0.000 claims description 3
- 235000015097 nutrients Nutrition 0.000 claims description 3
- 238000005063 solubilization Methods 0.000 claims description 3
- 230000007928 solubilization Effects 0.000 claims description 3
- 244000309466 calf Species 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 101710186708 Agglutinin Proteins 0.000 claims 2
- HSRJKNPTNIJEKV-UHFFFAOYSA-N Guaifenesin Chemical compound COC1=CC=CC=C1OCC(O)CO HSRJKNPTNIJEKV-UHFFFAOYSA-N 0.000 claims 2
- 101710146024 Horcolin Proteins 0.000 claims 2
- 101710189395 Lectin Proteins 0.000 claims 2
- 101710179758 Mannose-specific lectin Proteins 0.000 claims 2
- 101710150763 Mannose-specific lectin 1 Proteins 0.000 claims 2
- 101710150745 Mannose-specific lectin 2 Proteins 0.000 claims 2
- 239000000910 agglutinin Substances 0.000 claims 2
- 108010048090 soybean lectin Proteins 0.000 claims 2
- 108010058611 Helix lectin Proteins 0.000 claims 1
- 244000112675 Lablab purpureus Species 0.000 claims 1
- 125000003047 N-acetyl group Chemical group 0.000 claims 1
- 240000000528 Ricinus communis Species 0.000 claims 1
- 235000004443 Ricinus communis Nutrition 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 108010084962 lima bean lectin Proteins 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 abstract description 13
- 229940041181 antineoplastic drug Drugs 0.000 abstract description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 40
- 241000699670 Mus sp. Species 0.000 description 24
- 239000000872 buffer Substances 0.000 description 23
- 238000012360 testing method Methods 0.000 description 23
- 239000011780 sodium chloride Substances 0.000 description 21
- 102000004169 proteins and genes Human genes 0.000 description 19
- 108090000623 proteins and genes Proteins 0.000 description 19
- 241000699666 Mus <mouse, genus> Species 0.000 description 18
- 239000012980 RPMI-1640 medium Substances 0.000 description 16
- 208000005718 Stomach Neoplasms Diseases 0.000 description 16
- 206010017758 gastric cancer Diseases 0.000 description 16
- 201000011549 stomach cancer Diseases 0.000 description 16
- 239000001963 growth medium Substances 0.000 description 15
- 238000002360 preparation method Methods 0.000 description 14
- 239000012636 effector Substances 0.000 description 13
- 238000000926 separation method Methods 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 229920002684 Sepharose Polymers 0.000 description 12
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 12
- 239000003795 chemical substances by application Substances 0.000 description 12
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 12
- 230000003013 cytotoxicity Effects 0.000 description 12
- 231100000135 cytotoxicity Toxicity 0.000 description 12
- 239000000126 substance Substances 0.000 description 12
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 11
- 206010006187 Breast cancer Diseases 0.000 description 11
- 208000026310 Breast neoplasm Diseases 0.000 description 11
- 108010002350 Interleukin-2 Proteins 0.000 description 11
- 102000000588 Interleukin-2 Human genes 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- 210000004989 spleen cell Anatomy 0.000 description 11
- 239000013504 Triton X-100 Substances 0.000 description 9
- 229920004890 Triton X-100 Polymers 0.000 description 9
- 238000001042 affinity chromatography Methods 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 239000006228 supernatant Substances 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 8
- 239000002504 physiological saline solution Substances 0.000 description 8
- 210000000952 spleen Anatomy 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 210000001744 T-lymphocyte Anatomy 0.000 description 7
- 239000000969 carrier Substances 0.000 description 7
- 108010039433 dolichos biflorus agglutinin Proteins 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 230000000295 complement effect Effects 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000008363 phosphate buffer Substances 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 235000017557 sodium bicarbonate Nutrition 0.000 description 6
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- 239000012981 Hank's balanced salt solution Substances 0.000 description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 5
- 206010029260 Neuroblastoma Diseases 0.000 description 5
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 5
- 201000005202 lung cancer Diseases 0.000 description 5
- 208000020816 lung neoplasm Diseases 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 206010005003 Bladder cancer Diseases 0.000 description 4
- 208000011691 Burkitt lymphomas Diseases 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 102000007563 Galectins Human genes 0.000 description 4
- 108010046569 Galectins Proteins 0.000 description 4
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 229920005654 Sephadex Polymers 0.000 description 4
- 239000012507 Sephadex™ Substances 0.000 description 4
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 230000027455 binding Effects 0.000 description 4
- 238000001962 electrophoresis Methods 0.000 description 4
- 150000004676 glycans Chemical class 0.000 description 4
- 210000005104 human peripheral blood lymphocyte Anatomy 0.000 description 4
- 230000003100 immobilizing effect Effects 0.000 description 4
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 4
- 210000001165 lymph node Anatomy 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 239000005017 polysaccharide Substances 0.000 description 4
- DAJSVUQLFFJUSX-UHFFFAOYSA-M sodium;dodecane-1-sulfonate Chemical compound [Na+].CCCCCCCCCCCCS([O-])(=O)=O DAJSVUQLFFJUSX-UHFFFAOYSA-M 0.000 description 4
- 238000001179 sorption measurement Methods 0.000 description 4
- 201000005112 urinary bladder cancer Diseases 0.000 description 4
- 206010009944 Colon cancer Diseases 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 208000029742 colonic neoplasm Diseases 0.000 description 3
- 239000013256 coordination polymer Substances 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000002147 killing effect Effects 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 229920000936 Agarose Polymers 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- QRLVDLBMBULFAL-UHFFFAOYSA-N Digitonin Natural products CC1CCC2(OC1)OC3C(O)C4C5CCC6CC(OC7OC(CO)C(OC8OC(CO)C(O)C(OC9OCC(O)C(O)C9OC%10OC(CO)C(O)C(OC%11OC(CO)C(O)C(O)C%11O)C%10O)C8O)C(O)C7O)C(O)CC6(C)C5CCC4(C)C3C2C QRLVDLBMBULFAL-UHFFFAOYSA-N 0.000 description 2
- 201000009051 Embryonal Carcinoma Diseases 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 description 2
- 206010038389 Renal cancer Diseases 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 2
- 239000003945 anionic surfactant Substances 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 150000007514 bases Chemical class 0.000 description 2
- 230000002308 calcification Effects 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- UVYVLBIGDKGWPX-KUAJCENISA-N digitonin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)C[C@@H](O)[C@H](O[C@H]5[C@@H]([C@@H](O)[C@@H](O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)CO7)O)[C@H](O)[C@@H](CO)O6)O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O7)O)[C@@H](O)[C@@H](CO)O6)O)[C@@H](CO)O5)O)C[C@@H]4CC[C@H]3[C@@H]2[C@@H]1O)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 UVYVLBIGDKGWPX-KUAJCENISA-N 0.000 description 2
- UVYVLBIGDKGWPX-UHFFFAOYSA-N digitonine Natural products CC1C(C2(CCC3C4(C)CC(O)C(OC5C(C(O)C(OC6C(C(OC7C(C(O)C(O)CO7)O)C(O)C(CO)O6)OC6C(C(OC7C(C(O)C(O)C(CO)O7)O)C(O)C(CO)O6)O)C(CO)O5)O)CC4CCC3C2C2O)C)C2OC11CCC(C)CO1 UVYVLBIGDKGWPX-UHFFFAOYSA-N 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 150000002016 disaccharides Chemical class 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 238000001114 immunoprecipitation Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 229960000905 indomethacin Drugs 0.000 description 2
- 201000010982 kidney cancer Diseases 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 229960004857 mitomycin Drugs 0.000 description 2
- 239000002736 nonionic surfactant Substances 0.000 description 2
- 229920001542 oligosaccharide Chemical group 0.000 description 2
- 150000002482 oligosaccharides Chemical group 0.000 description 2
- 108010086652 phytohemagglutinin-P Proteins 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000001235 sensitizing effect Effects 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
- 101001072765 Homo sapiens Neutral alpha-glucosidase AB Proteins 0.000 description 1
- VLHUSFYMPUDOEL-WZTVWXICSA-N Iothalamate meglumine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CNC(=O)C1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I VLHUSFYMPUDOEL-WZTVWXICSA-N 0.000 description 1
- 208000006552 Lewis Lung Carcinoma Diseases 0.000 description 1
- 241000282564 Macaca fuscata Species 0.000 description 1
- 101000934342 Mus musculus T-cell surface glycoprotein CD5 Proteins 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- 102100036592 Neutral alpha-glucosidase AB Human genes 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000009097 Phosphorylases Human genes 0.000 description 1
- 108010073135 Phosphorylases Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 208000007452 Plasmacytoma Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000000389 T-cell leukemia Diseases 0.000 description 1
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- -1 acetyl - Chemical class 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 125000000853 cresyl group Chemical group C1(=CC=C(C=C1)C)* 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- HBNYJWAFDZLWRS-UHFFFAOYSA-N ethyl isothiocyanate Chemical compound CCN=C=S HBNYJWAFDZLWRS-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 108010065337 fluorescein isothiocyanate-peanut agglutinin Proteins 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000989 no adverse effect Toxicity 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- HFZNPKDYLSOGBE-SCEMAYBHSA-N nrc-12 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(C)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CN)C(C)C)[C@@H](C)O)C(C)C)C(C)C)C1=CC=C(O)C=C1 HFZNPKDYLSOGBE-SCEMAYBHSA-N 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 210000002741 palatine tonsil Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- OQUKIQWCVTZJAF-UHFFFAOYSA-N phenol;sulfuric acid Chemical compound OS(O)(=O)=O.OC1=CC=CC=C1 OQUKIQWCVTZJAF-UHFFFAOYSA-N 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- ZNNZYHKDIALBAK-UHFFFAOYSA-M potassium thiocyanate Chemical compound [K+].[S-]C#N ZNNZYHKDIALBAK-UHFFFAOYSA-M 0.000 description 1
- 229940116357 potassium thiocyanate Drugs 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000009696 proliferative response Effects 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000007788 roughening Methods 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000010414 supernatant solution Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 238000001771 vacuum deposition Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP56156413A JPS5857318A (ja) | 1981-10-01 | 1981-10-01 | 癌細胞障害性リンパ球の製造法 |
| JP15641481A JPS5857321A (ja) | 1981-10-01 | 1981-10-01 | 抗癌剤 |
| JP56158473A JPS5859923A (ja) | 1981-10-05 | 1981-10-05 | 抗癌剤 |
| JP56158472A JPS5859922A (ja) | 1981-10-05 | 1981-10-05 | 癌細胞障害性リンパ球 |
| JP57111168A JPS591420A (ja) | 1982-06-28 | 1982-06-28 | 糖鎖関連抗原およびその製造法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DD221917A5 true DD221917A5 (de) | 1985-05-08 |
Family
ID=27526479
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DD82261475A DD221917A5 (de) | 1981-10-01 | 1982-06-30 | Verfahren zur herstellung von krebszellen-cytotoxischen lymphocyten |
| DD82241290A DD209577A5 (de) | 1981-10-01 | 1982-06-30 | Verfahren zur herstellung eines glykoverwandten antigens |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DD82241290A DD209577A5 (de) | 1981-10-01 | 1982-06-30 | Verfahren zur herstellung eines glykoverwandten antigens |
Country Status (19)
| Country | Link |
|---|---|
| AR (1) | AR230731A1 (fi) |
| AT (2) | AT382080B (fi) |
| AU (1) | AU554858B2 (fi) |
| BE (1) | BE893704A (fi) |
| CA (1) | CA1195269A (fi) |
| CH (2) | CH655660B (fi) |
| DD (2) | DD221917A5 (fi) |
| DE (2) | DE3249568A1 (fi) |
| DK (1) | DK292182A (fi) |
| FI (1) | FI77157C (fi) |
| FR (1) | FR2513882B1 (fi) |
| IL (1) | IL66270A (fi) |
| IT (1) | IT1189305B (fi) |
| MX (1) | MX7437E (fi) |
| NL (1) | NL8202638A (fi) |
| NO (1) | NO161601C (fi) |
| NZ (1) | NZ201112A (fi) |
| PT (1) | PT75148B (fi) |
| SE (1) | SE8204058L (fi) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0334300A1 (en) * | 1988-03-21 | 1989-09-27 | Neorx Corporation | The use of monoclonal antibodies and conjugates thereof as signals to direct sensitized effector cells to tumor sites |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60214737A (ja) * | 1984-04-06 | 1985-10-28 | Nippon Koutai Kenkyusho:Kk | 糖鎖関連抗原の製造法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1193378A (en) * | 1967-04-11 | 1970-05-28 | Rand Dev Corp | Cancer Antigen Complexes |
| DE1943699A1 (de) * | 1969-08-28 | 1971-03-04 | Stiftung Onophrio | Heilmittel mit proliferationshemmender Wirkung und Verfahren zur Herstellung dieses Heilmittels |
| YU34005B (en) * | 1970-02-24 | 1978-10-31 | Podvinec Srecko | Process for obtaining bovine lymphatic gland extract |
| US4371515A (en) * | 1978-12-26 | 1983-02-01 | E-Y Laboratories, Inc. | Method for forming an isolated lectin-immunological conjugate |
-
1982
- 1982-06-29 FI FI822325A patent/FI77157C/fi not_active IP Right Cessation
- 1982-06-29 NZ NZ201112A patent/NZ201112A/en unknown
- 1982-06-29 PT PT75148A patent/PT75148B/pt not_active IP Right Cessation
- 1982-06-29 NO NO822215A patent/NO161601C/no unknown
- 1982-06-29 DK DK292182A patent/DK292182A/da not_active Application Discontinuation
- 1982-06-30 FR FR8211489A patent/FR2513882B1/fr not_active Expired
- 1982-06-30 CH CH398882A patent/CH655660B/de unknown
- 1982-06-30 AU AU85458/82A patent/AU554858B2/en not_active Ceased
- 1982-06-30 CH CH551284A patent/CH655661B/de unknown
- 1982-06-30 DD DD82261475A patent/DD221917A5/de not_active IP Right Cessation
- 1982-06-30 IT IT48724/82A patent/IT1189305B/it active
- 1982-06-30 BE BE0/208493A patent/BE893704A/fr not_active IP Right Cessation
- 1982-06-30 MX MX8210163U patent/MX7437E/es unknown
- 1982-06-30 AR AR289864A patent/AR230731A1/es active
- 1982-06-30 DD DD82241290A patent/DD209577A5/de not_active IP Right Cessation
- 1982-06-30 SE SE8204058A patent/SE8204058L/xx not_active Application Discontinuation
- 1982-06-30 NL NL8202638A patent/NL8202638A/nl not_active Application Discontinuation
- 1982-07-08 IL IL66270A patent/IL66270A/xx unknown
- 1982-09-30 DE DE19823249568 patent/DE3249568A1/de active Granted
- 1982-09-30 DE DE19823236298 patent/DE3236298A1/de active Granted
- 1982-10-01 AT AT0363782A patent/AT382080B/de not_active IP Right Cessation
- 1982-10-01 CA CA000412670A patent/CA1195269A/en not_active Expired
-
1985
- 1985-12-09 AT AT0354585A patent/AT390002B/de not_active IP Right Cessation
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0334300A1 (en) * | 1988-03-21 | 1989-09-27 | Neorx Corporation | The use of monoclonal antibodies and conjugates thereof as signals to direct sensitized effector cells to tumor sites |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3689071T2 (de) | Immunheilbehandlung. | |
| DE69125735T2 (de) | Verfahren zur Aktivierung der zytolytischen Wirkung von Lymphozyten unter Verwendung von anti-CD28-Antikörper | |
| DE3852054T2 (de) | Monoklonale Antikörper gegen Glycolipid-Antigene und ihre Verwendung. | |
| CH655010A5 (de) | Pharmazeutischer wirkstoff mit antitumoraktivitaet. | |
| DE3751553T2 (de) | Immunomodulare mittel und deren verwendung. | |
| JPS6133008B2 (fi) | ||
| DE69110060T2 (de) | In der humantherapie nützliche substanzen peptidischer natur. | |
| Bajaj et al. | Immunomodulatory activity of a Unani gold preparation used in Indian system of medicine | |
| JP4744782B2 (ja) | 癌の治療のための化学療法剤との多糖の同時投与 | |
| DE69627780T2 (de) | Peptid das eine Immunantwort gegen menschlichen Magenkrebs induziert und Arzneimittel die es enthält zur Vorbeugung oder Behandlung von Magenkrebs | |
| GB2106935A (en) | Cancer cell-combatting lymphocytes process, for the production thereof, and anticancer agents containing said lymphocytes | |
| DD221917A5 (de) | Verfahren zur herstellung von krebszellen-cytotoxischen lymphocyten | |
| CZ186897A3 (cs) | Použití molekul, schopných vázat MHC-II nebo napodobujících MHC-II pro výrobu farmaceutického prostředku | |
| DE69624586T2 (de) | Peptidvakzine auf basis von fusionsproteinen mit onkogenanteil | |
| DE69429657T2 (de) | Verwendung von modifizierten tall-104 zellen zur behandlung von krebs und viralen krankheiten | |
| DE69527640T2 (de) | Zusammensetzungen die gemischte transferrine als wirkstoff für induktion von immunotoleranz gegen antigen enthalten | |
| AU593210B2 (en) | Process for preparing glycosidic linkage related antigen | |
| FI80711B (fi) | Foerfarande foer framstaellning av en terapeutiskt anvaendbar termiskt denaturerad, till en glykosidbindning ansluten antigen (gra), som haerroer sig fraon cancerceller. | |
| Litt | Studies in experimental eosinophilia. II. Induction of peritoneal eosinophilia by the transfer of tissues and tissue extracts | |
| CA1201988A (en) | Cancer cell-combatting lymphocytes, process for the production thereof and anticancer agents containing said lymphocytes | |
| DE3123830A1 (de) | "antivirussubstanz und verfahren zu ihrer herstellung" | |
| DE4204132C2 (de) | Aufbereitung für die Gewinnung von Vakzinen für eine Immuntherapie | |
| KR100209180B1 (ko) | 아세만난을 포함하는 약제학적 조성물 | |
| KR960004028B1 (ko) | 면역증강제 조성물 | |
| NZ214000A (en) | Method of sensitising lymphocytes to cancer associated antigens |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ENJ | Ceased due to non-payment of renewal fee |